These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
228 related items for PubMed ID: 11331333
1. Predicting outcome to chemotherapy in patients with germ cell tumors: the value of the rate of decline of human chorionic gonadotrophin and alpha-fetoprotein during therapy. Mazumdar M, Bajorin DF, Bacik J, Higgins G, Motzer RJ, Bosl GJ. J Clin Oncol; 2001 May 01; 19(9):2534-41. PubMed ID: 11331333 [Abstract] [Full Text] [Related]
2. Serum tumor marker decline is an early predictor of treatment outcome in germ cell tumor patients treated with cisplatin and ifosfamide salvage chemotherapy. Murphy BA, Motzer RJ, Mazumdar M, Vlamis V, Nisselbaum J, Bajorin D, Bosl GJ. Cancer; 1994 May 15; 73(10):2520-6. PubMed ID: 7513603 [Abstract] [Full Text] [Related]
9. [Result of treatment for advanced germ cell tumor in the last decade]. Ishioka J, Kageyama Y, Inoue M, Fukui N, Numao N, Saito K, Ichiyanagi N, Tanak M, Hyochi N, Fukuda H, Higashi Y. Nihon Hinyokika Gakkai Zasshi; 2010 Mar 01; 101(3):539-46. PubMed ID: 20387513 [Abstract] [Full Text] [Related]
10. AFP and HCG in germ cell tumors. Bassetto MA, Franceschi T, Lenotti M, Parise G, Pancheri F, Sabbioni R, Zaninelli M, Cetto GL. Int J Biol Markers; 1994 Mar 01; 9(1):29-32. PubMed ID: 7519651 [Abstract] [Full Text] [Related]
13. Serum tumor marker half-life during chemotherapy in patients with germ cell tumors. Bosl GJ, Head MD. Int J Biol Markers; 1994 Mar 01; 9(1):25-8. PubMed ID: 7519650 [Abstract] [Full Text] [Related]
14. Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors. Hartmann JT, Nichols CR, Droz JP, Horwich A, Gerl A, Fossa SD, Beyer J, Pont J, Kanz L, Einhorn L, Bokemeyer C. Ann Oncol; 2002 Jul 01; 13(7):1017-28. PubMed ID: 12176779 [Abstract] [Full Text] [Related]
15. The prognostic impact of different tumor marker levels in nonseminomatous germ cell tumor patients with intermediate prognosis: A registry of the International Global Germ Cell Tumor Collaborative Group (G3). Seidel C, Daugaard G, Tryakin A, Necchi A, Cohn-Cedermark G, Ståhl O, Hentrich M, Brito M, Albany C, Taza F, Gerl A, Oechsle K, Oing C, Bokemeyer C. Urol Oncol; 2019 Nov 01; 37(11):809.e19-809.e25. PubMed ID: 31494007 [Abstract] [Full Text] [Related]